Anteris Technologies posted a $20.8M quarterly cash burn as its PARADIGM trial for DurAVR enrolled its first U.S. patients under a CMS reimbursement framework. The cash drain and trial pace shape the path to commercialization.
Alpha Score of 53 reflects moderate overall profile with moderate momentum, moderate value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Anteris Technologies burned $20.8 million in operating cash during the second quarter as its PARADIGM trial for the DurAVR heart valve moved into U.S. patient enrollment. Research and development costs hit $23.4 million, driven by manufacturing scale-up and clinical staffing, the company said in its Aug. 11 earnings release.
The PARADIGM trial, a global pivotal study for the DurAVR transcatheter heart valve, is recruiting at active European sites and began U.S. enrollment after the Centers for Medicare and Medicaid Services issued a coverage determination in April. Eligible procedures at participating U.S. study sites fall under the TAVR National Coverage Determination 20.32, removing a reimbursement barrier for patients and hospitals.
CEO Wayne Paterson called the quarter an important period of execution. He cited the CMS decision, the U.S. trial launch, and expanded recruitment across geographies. The company added to its board during the period, he said.
Cash burn remains the key risk for Anteris, a pre-revenue developer. The $20.8 million quarterly outflow does not include any disclosed cash balance. Anteris has raised capital through equity offerings in the past and may need to do so again before reaching a commercial stage. The company did not provide guidance on its runway.
Australian sites are progressing through initial start-up documentation, with activation and patient recruitment to follow subject to ethics committee approval at each site. Clinical centers are working through ethics and regulatory approvals, site initiation visits, and investigator training, alongside patient screening and enrollment at activated sites. The company expects U.S. site activation and recruitment to continue advancing as additional centers contribute.
A faster enrollment pace would improve the outlook. A slowdown in site activation or patient recruitment would extend the cash need. The company has not disclosed interim data timelines for the PARADIGM trial, which requires full enrollment to support a premarket approval application with the FDA. Any delay in recruitment or regulatory review would add pressure on the balance sheet.
Partnership or non-dilutive funding could reduce the risk. The CMS reimbursement framework already removes one barrier for hospitals. The next catalysts to watch are enrollment updates and any financing announcement. The company's Q2 results showed R&D spending also included process development and validation activities and expanded headcount, together with clinical costs tied to patient enrollment and scaling the field-based clinical team. These costs were partly offset by reduced DurAVR THV product research costs.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.